NANJING SANHOME PHARMACEUTICAL CO., LTD. Patent applications |
Patent application number | Title | Published |
20150361123 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF - A novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection is provided. The pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound has a good anti-HCV effect. | 12-17-2015 |
20150299202 | HETEROARYL ALKYNE COMPOUND AND USE THEREOF - In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors. | 10-22-2015 |
20150152088 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF - The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to compounds having an alkynyl heteroaromatic ring structure and pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates, or prodrugs thereof, and pharmaceutical compositions comprising these compounds, as well as uses of these compounds and compositions in the manufacture of a medicament. The compounds of the present invention and the pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates or prodrugs thereof and the pharmaceutical compositions comprising the compounds have better anti-tumor activity. | 06-04-2015 |
20140128384 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE - The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect. | 05-08-2014 |
20130202698 | L-ORNIDAZOLE FORMULATIONS AND THEIR APPLICATIONS IN TREATMENT OF PARASITIC INFECTIONS - This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed. | 08-08-2013 |
20100204324 | Optically Active N-(Alpha-Mercaptopropionyl)Glycine - An optically active N-(α-mercaptopropionyl)glycine, i.e., R-(−)-N-(α-mercaptopropionyl)glycine or S-(−)-N-(α-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceutically acceptable salt or ester thereof, and use of the same in preparation of detoxification medicament for improving metabolism, are provided. | 08-12-2010 |
20090326030 | Use of Levo-Ornidazole in the Preparation of Anti-Anaerobic Bacteria Infection Drugs - The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses. | 12-31-2009 |